Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.

doi:10.1158/1078-0432.CCR-23-3785

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 2 Dec 2024

Chou Jonathan, Robinson Troy M, Egusa Emily A, Lodha Roshan, Zhang Meng, Badura Michelle, Mikayelyan Mane, Delavan Henry M, Swinderman Jason, Wilson Chris, Zhu Jun, Das Rajdeep, Nguyen Minh, Loehr Andrea, Golsorkhi Tony, Simmons Andrew, Abida Wassim, Chinnaiyan Arul M, Arkin Michelle R, Small Eric J, Quigley David A, Yang Lixing, Kim Minkyu, Ashworth Alan, Feng Felix Y

Abstract excerpt

PURPOSE: The cyclin-dependent kinase (CDK), CDK12, is mutated or amplified in multiple cancers. We previously described a subtype of prostate cancer characterized predominantly by frameshift, loss-of-function mutations in CDK12. This subtype exhibits aggressive clinical features. EXPERIMENTAL DESIGN: Using isogenic prostate cancer models generated by CRISPR/Cas9-mediated inactivation of CDK12, we conducted a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinases

Share to Indoles

Share to Mice

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms

Share to Synthetic Lethal Mutations

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39321214
DOI: 10.1158/1078-0432.CCR-23-3785
PMCID: PMC11611633

Genes

CDK12
CDK13

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.PMID 39321214Read ↗

<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalitySemantic proximity Read ↗

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Semantic proximity Read ↗

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancerSemantic proximity Read ↗

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read ↗

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read ↗

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read ↗

Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate TumorsSemantic proximity Read ↗

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategiesSemantic proximity Read ↗

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read ↗

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivitiesSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.